Navigation Links
PrimeraDx Appoints Leroy Hood to its Scientific Advisory Board
Date:12/6/2011

MANSFIELD, Mass., Dec. 6, 2011 /PRNewswire/ -- PrimeraDx today announced that Leroy Hood, MD, PhD, a world recognized leader in the molecular device industry, has been appointed to its Scientific Advisory Board. 

"High multiplex qPCR diagnostics is a key step in bringing personalized medicine to the clinic," commented Dr. Hood.  "I am delighted to help PrimeraDx take the step from an innovative next generation qPCR platform to a robust molecular diagnostics solution."

"Lee brings a breadth of knowledge in the molecular device industry that no one else has.  With Lee's scientific vision we will move forward with our goal of transforming molecular diagnostic medicine and improving patient care," said President and CEO Matthew McManus.

Dr. Hood has established a systems approach to understanding the complexity of biology and medicine.  He has played a pivotal role in the DNA sequencing industry and his innovations were essential for the sequencing of the human genome.  Dr. Hood has been instrumental in the founding of numerous research and commercial enterprises, including Applied Biosystems, Amgen and the Institute for System Biology, where he currently holds the position of President.  He has won several awards and accolades, including; the 2003 AMP award for excellence in Molecular Diagnostics, the Academy of Engineering's Russ Prize, the Lasker Award and the Kyoto Prize.  Dr. Hood has more than 700 peer reviewed articles and is a member of the National Academy of Sciences, the National Academy of Engineering and the Institute of Medicine.

About PrimeraDx

PrimeraDx is a molecular diagnostics company that has developed, and is commercializing, a novel, game-changing clinical platform which combines PCR with capillary electrophoresis.  The result of combining these two well-known technologies into a bench-top instrument is the ability to deliver highly multiplexed and quantitative answers to the clinic.  The company is pursuing a two pronged strategy to sell the system in an Open Platform Mode to clinical labs and to collaborate with pharmaceutical companies to develop high-value companion and enabling diagnostic products.  Users can easily design very complex multi-modal assays that test for disparate target types, like SNPs, expression biomarkers, microRNAs and fusion genes.  PrimeraDx's technology represents the next generation of quantitative PCR.  The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation.  The Company's website is: www.primeradx.com or www.multiplexpcr.com.

CONTACT: Andrew Bond, +1-508-618-2752, abond@primeradx.com


'/>"/>
SOURCE PrimeraDx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PrimeraDx Appoints David Heffelfinger as VP of Engineering and Systems Development
2. PrimeraDx Launches the Only System Capable of Simultaneous Quantification of mRNA, microRNA and DNA
3. Ulthera Appoints Greg Waller as Chief Financial Officer
4. Tengion Appoints John L. Miclot President and Chief Executive Officer
5. Remedi SeniorCare® Appoints Corey Gauff SVP of Sales and Account Management
6. Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team
7. CVS Caremark Appoints Kevin Murphy President of Accordant Business
8. Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer
9. Adeona Appoints Jeff Lucero Riley as Independent Chairman
10. Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation
11. InterMune Appoints Angus C. Russell to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... ... presenting the latest in wound care advancements to physician colleagues, skilled nursing facility ... is titled, "Navigating the Treacherous Waters of Wound Care." , "At many of ...
Breaking Medicine News(10 mins):